Delusional disorder

Summary

Delusional disorder (MONDO:0004359) is a disease and 28 clinical trials. Top therapeutic interventions include ziprasidone, agomelatine, and benztropine. A subtype of psychotic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 28

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	delusional disorder
Mondo ID	MONDO:0004359
DOID	DOID:778
ICD-11	1974996783
NCIT	C94379
SNOMED CT	48500005
UMLS	C0011251
MedGen	8276
Is cancer (heuristic)	no

Disease family

This is a subtype of psychotic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › delusional disorder

Related subtypes (7): schizophreniform disorder, alcoholic psychosis, substance-induced psychosis, schizophrenia, methamphetamine-induced psychosis, schizoaffective disorder, postpartum psychosis

Subtypes (1): Capgras syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 28.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	21
PHASE4	4
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00644800	PHASE4	COMPLETED	A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
NCT01822418	PHASE4	COMPLETED	Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
NCT01981759	PHASE4	COMPLETED	D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
NCT03559426	PHASE4	COMPLETED	Research Into Antipsychotic Discontinuation and Reduction Trial
NCT00300651	PHASE3	UNKNOWN	Trial of Cognitive Behavioral Therapy for Schizophrenia
NCT04323566	PHASE2	ENROLLING_BY_INVITATION	Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
NCT00465920	PHASE2	UNKNOWN	Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis
NCT04916626	Not specified	ACTIVE_NOT_RECRUITING	The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
NCT05416658	Not specified	NOT_YET_RECRUITING	Shared Decision Making for Antipsychotic Medications
NCT05756855	Not specified	ACTIVE_NOT_RECRUITING	Young Adults With Violent Behavior During Early Psychosis (Aim 2)
NCT06005766	Not specified	RECRUITING	The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care
NCT06336382	Not specified	RECRUITING	Tau Biomarkers in Late-onset Psychosis (LOP)
NCT06423651	Not specified	RECRUITING	Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
NCT06740383	Not specified	RECRUITING	Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
NCT06898879	Not specified	NOT_YET_RECRUITING	Enhancing Veteran-Clinical Collaboration in VA PRRCs
NCT00222807	Not specified	COMPLETED	Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
NCT00617214	Not specified	TERMINATED	Schizophrenic Patients Taking Part in Integrated Care Program
NCT00657631	Not specified	COMPLETED	Acceptance and Commitment Therapy for Delusions
NCT00715377	Not specified	TERMINATED	Anticholinergic Burden in Schizophrenia
NCT00716755	Not specified	COMPLETED	Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
NCT01216891	Not specified	COMPLETED	Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
NCT01888627	Not specified	UNKNOWN	Integrated Care in Psychotic Disorders With Severe Mental Illness
NCT02787122	Not specified	COMPLETED	Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia
NCT04324944	Not specified	COMPLETED	Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness
NCT04783285	Not specified	COMPLETED	Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders
NCT04874974	Not specified	COMPLETED	Feasibility of a Novel Process-based Treatment for Patients With Psychosis
NCT05824117	Not specified	UNKNOWN	Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.
NCT06007105	Not specified	UNKNOWN	SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ZIPRASIDONE	4	3
AGOMELATINE	4	1
BENZTROPINE	4	1
CYCLOSERINE	4	1
LEVCYCLOSERINE	2	1
CHEMBL116590	0	1